Introduction {#section1-1533033819841061}
============

Jaw tracking (JT) is a technique that was provided by Varian TrueBeam series, where the jaw can track the aperture of the multileaf collimator (MLC) to reduce the leakage and transmission and thus reduce doses of normal tissues around the tumor.^[@bibr1-1533033819841061],[@bibr2-1533033819841061]^ Most publications discussed the dose changes in several kinds of tumors, but very few articles studied the impact of tumor sizes and very few compared the intensity-modulated radiation therapy (IMRT) quality assurance (QA) verification results. Therefore, this study investigated the dose change in organ-at-risks (OARs), and the verification results of plans with JT both in large and in small tumors were compared to no JT (NJT), expecting the results can be beneficial for clinical treatment. In this study, we investigated the impact of JT on dose to OARs and the verification results (γ passing rates) of plans with large and small tumors.

Materials and Methods {#section2-1533033819841061}
=====================

Varian EDGE with HD120 MLC is used in the study, and the maximum field size with MLC is 40 × 22 cm. The width of MLC is 2.5 ´ 32 mm at the center and 5 ´ 28 mm at the peripheral. Portal Vision AS1200 with portal dosimetry (PD) is used for plan verification. AS1200 detector has an active area of 40 × 40 cm^2^ with 1190 × 1190 pixel arrays and pixel pitch of 0.336 mm which is suitable for both large- and small-field verification.^[@bibr3-1533033819841061][@bibr4-1533033819841061]-[@bibr5-1533033819841061]^ The treatment planning system is Eclipse v13.6.

In this study, 8 static IMRT cases of nasopharyngeal carcinoma (NPC) and 8 static IMRT cases of single brain metastasis were chosen. All plans used sliding window technique with 6 MV photon beam. For NPC cases, 9 coplanar fields with 40° separation were used, and for brain metastasis cases, 10 to 12 noncoplanar fields were used. In each case, the JT IMRT plan was first designed, and the NJT plan was obtained from the JT IMRT plan by recalculating MLC sequence with no JT. The target doses of the 2 techniques were normalized to 95% volume of target received prescription dose in order to ensure the same target coverage. Meanwhile, the total monitor units (MUs) and doses of the normal tissues with the 2 techniques were compared by paired *t* test using SPSS22 Statistics Analysis Software. *P* \< .05 was considered statistically significant.

All plans were verified with Varian PD. Composite fluence of all fields in one plan was used for γ analysis and 2 criteria were used for γ analysis: 3 mm, 3%, threshold 10% and 2 mm, 2%, threshold 10%.^[@bibr6-1533033819841061]^

Results {#section3-1533033819841061}
=======

Target Volume {#section4-1533033819841061}
-------------

For NPC cases, all planning target volumes (PTVs) were combined to one target for volume measuring, and the target volume of brain metastasis was the PTV. All the target volumes are listed in [Table 1](#table1-1533033819841061){ref-type="table"}.

###### 

Target Volumes of NPC and Brain Metastasis.

![](10.1177_1533033819841061-table1)

                            P1      P2      P3      P4      P5      P6      P7      P8      Mean
  ------------------------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  NPC, cm^3^                751.6   569.0   562.8   768.0   632.2   562.2   510.9   623.5   622.5
  Brain metastasis, cm^3^   9.9     7.1     7.5     5.8     8.6     5.3     9.6     7.2     7.6

Abbreviation: NPC, nasopharyngeal carcinoma.

Dose of OARs {#section5-1533033819841061}
------------

By comparing the dose--volume histogram (DVH) of OARs in JT and NJT plans for NPC, we found that both the maximum and mean doses of OARs in JT plans are lower than in NJT plans. [Figure 1](#fig1-1533033819841061){ref-type="fig"} shows the DVH comparison of OARs between JT and NJT of a representative patient (P1). The statistical analysis results are shown in [Table 2](#table2-1533033819841061){ref-type="table"}.

![Dose--volume histogram (DVH) comparison of nasopharyngeal carcinoma (NPC) organs at risk (OARs) of jaw tracking (JT) and no JT (NJT).](10.1177_1533033819841061-fig1){#fig1-1533033819841061}

###### 

OAR Dose Comparison of Cases With NPC Between JT and NJT.

![](10.1177_1533033819841061-table2)

  OARs             Items               Jaw Tracking, cGy   No Jaw Tracking, cGy   Reduction,%   *P*
  ---------------- ------------------- ------------------- ---------------------- ------------- -------
  Brain stem       Dmax                4478.98 ± 393.89    4531.56 ± 391.94       1.16          .000
  Dmean            2593.29 ± 286.74    2687.36 ± 303.35    3.51                   .000          
  Spinal cord      Dmax                3762.26 ± 141.11    3889.32 ± 153.08       3.27          .000
  Dmean            2436.77 ± 362.40    2521.12 ± 377.44    3.34                   .000          
  Eyes             Dmax                1803.55 ± 1093.11   1921.21 ± 1096.24      6.12          .000
  Dmean            484.72 ± 139.43     577.59 ± 143.70     16.08                  .000          
  Lens             Dmax                445.27 ± 86.53      540.71 ± 98.60         17.65         .000
  Dmean            362.04 ± 47.80      448.72 ± 53.35      19.32                  .000          
  Optical nerves   Dmax                2351.25 ± 1783.81   2428.11 ± 1466.26      3.16          .000
  Dmean            1045.06 ± 867.02    1123.91 ± 881.69    7.01                   .000          
  Optical chiasm   Dmax                2672.16 ± 2043.14   2714.75 ± 2045.55      1.57          0.000
  Dmean            1449.72 ± 1038.35   1527.45 ± 1044.71   5.09                   .000          
  Larynx           Dmax                6292.50 ± 407.59    6331.44 ± 421.79       0.61          0.003
  Dmean            3421.59 ± 455.55    3497.37 ± 460.96    2.17                   .000          

Abbreviations: JT, jaw tracking; NJT, no jaw tracking; NPC, nasopharyngeal carcinoma; OAR, organs at risk.

The maximum and mean doses of OARs in JT are smaller than in NJT, as shown in [Table 2](#table2-1533033819841061){ref-type="table"}. The dose of lens reduced the most in JT plans, with the Dmax and Dmean reduced by 17.65% and 19.32%, respectively, while the impact on dose to larynx was not as significant, where Dmax and Dmean reduced by 0.61% and 2.17%, respectively. The reason could be that most part of the larynx is within the target volume, and the JT won't impact the dose as significant as out-of-field OARs. For all the OARs assessed in [Table 2](#table2-1533033819841061){ref-type="table"}, it is demonstrated that JT technique has a significant reduction in all OAR doses (Dmax and Dmean) when compared to NJT technique (*P* \< .05).

In the single brain metastasis cases, the dose of OARs is also reduced in JT compared to NJT, but not as significant as that in NPC cases. [Figure 2](#fig2-1533033819841061){ref-type="fig"} shows the DVH comparison of OARs in the JT and NJT plans for single brain metastasis of a representative patient (P1). Although the DVH curve of each organ in JT is lower than NJT in [Figure 2](#fig2-1533033819841061){ref-type="fig"}, the difference is not obvious. This trend can also be observed in [Table 3](#table3-1533033819841061){ref-type="table"}.

![Single brain metastasis dose--volume histogram (DVH) comparison of jaw tracking (JT) and no JT (NJT).](10.1177_1533033819841061-fig2){#fig2-1533033819841061}

###### 

OAR Doses Comparison of Single Brain Metastases Between JT and NJT.

![](10.1177_1533033819841061-table3)

  OARs             Items             Jaw Tracking, cGy   No Jaw Tracking, cGy   Reduction,%   *P*
  ---------------- ----------------- ------------------- ---------------------- ------------- ------
  Brain stem       Dmax              1101.56 ± 997.20    1114.46 ± 1004.23      1.16          .013
  Dmean            295.89 ± 355.33   298.95 ± 356.23     1.02                   .000          
  Eyes             Dmax              251.11 ± 165.52     253.24 ± 165.23        0.84          .000
  Dmean            107.72 ± 60.27    109.67 ± 60.23      1.78                   .004          
  Lens             Dmax              145.06 ± 80.46      147.30 ± 81.22         1.52          .012
  Dmean            115.27 ± 79.76    116.37 ± 80.01      0.90                   0.002         
  Optical nerve    Dmax              208.81 ± 79.9       211.92 ± 78.65         1.47          .013
  Dmean            113.30 ± 72.46    115.45 ± 72.47      1.86                   .001          
  Optical chiasm   Dmax              229.11 ± 183.06     232.23 ± 182.67        1.34          .005
  Dmean            154.17 ± 134.40   156.62 ± 134.57     1.56                   .005          

Abbreviations: JT, jaw tracking; NJT, no jaw tracking; OAR, organs at risk.

From [Table 3](#table3-1533033819841061){ref-type="table"}, the OAR dose difference in JT and NJT plans is small: The reduction in Dmax ranges from 0.84% to 1.52% and the reduction in Dmean ranges from 0.9% to 1.86%, with *P* values all \<.05. For the single brain tumor, the field size is small and the jaw size will not change much between JT and NJT, so the differences in the MLC leakage and transmission will be very small.

Verification Results and MU Comparison {#section6-1533033819841061}
--------------------------------------

Plans with either technique must be verified to ensure the deliver accuracy. This study verified all JT and NJT plans, and the results are shown in [Table 4](#table4-1533033819841061){ref-type="table"}.

###### 

γ Pass Rate Comparison Between JT and NJT.

![](10.1177_1533033819841061-table4)

                   Criteria         JT             NJT            *P*
  ---------------- ---------------- -------------- -------------- ------
  NPC              3mm, 3%, th10%   99.89 ± 0.06   99.56 ± 0.19   .127
  2mm, 2%, th10%   97.15 ± 0.98     91.90 ± 1.40   .000           
  Brain            3mm, 3%, th10%   99.97 ± 0.05   99.44 ± 1.24   .251
  2mm, 2%, th10%   98.65 ± 1.27     93.35 ± 2.72   .000           

Abbreviations: JT, jaw tracking; NJT, no jaw tracking; NPC, nasopharyngeal carcinoma.

The γ pass rates of JT and NJT are slightly different at the 3 mm, 3%, and th10% γ pass criteria. Although the pass rates of JT are a little higher than NJT, the *P* values are \>.05. Therefore, there is no significant difference between the 2 plans with the 3 mm, 3%, and th10% criteria. With the criteria of 2 mm, 2%, and th10%, the pass rates of JT plans are significantly higher than NJT technique both in large and in small tumors, with all the *P* values \<.05.

We also compared the total MUs of JT and NJT plans. [Table 5](#table5-1533033819841061){ref-type="table"} shows the statistical results. The MUs of JT plans increased slightly compared to those of NJT plans, with the mean MU of NPC plan increased by 2.41% and the mean MU of brain metastasis plan increased by 1.10%.

###### 

MU Comparison between JT and NJT.

![](10.1177_1533033819841061-table5)

          JT               NJT              *P*
  ------- ---------------- ---------------- ------
  NPC     1413.6 ± 106.0   1380.3 ± 103.2   .000
  Brain   1264.6 ± 41.9    1250.8 ± 41.2    .000

Abbreviations: JT, jaw tracking; MU, monitor unit; NJT, no jaw tracking.

Discussion {#section7-1533033819841061}
==========

The article compared the doses of OARs (mean and maximum) and the plan verification results between JT and NJT static IMRT plans in small and large tumors. We found that the mean and maximal doses of OARs in JT plans were all lower than NJT plans with the same target coverage that is consistent with the results of other articles.^[@bibr7-1533033819841061][@bibr8-1533033819841061][@bibr9-1533033819841061][@bibr10-1533033819841061]-[@bibr11-1533033819841061]^ The transmission of Varian HD MLC is about 1.2% for 6MV,^[@bibr12-1533033819841061]^ and the jaw transmission is \<0.5%, so it is easier to reduce the OAR dose with JT. For small lesions, the field size is small, so the leakage to the OARs is also small. The impact of JT is more obvious in large tumor because the JT technique can block more MLC transmission in large field and reduce dose to out-of-field OARs. This finding is very helpful for plan design and can be specially applied in cases where low-dose sensitive normal tissues, such as the lung,^[@bibr13-1533033819841061][@bibr14-1533033819841061]-[@bibr15-1533033819841061]^ are close to the treatment target. At the same time, JT technique can reduce the risk of secondary tumors in patients with longer survival periods, such as patients with breast cancer.^[@bibr16-1533033819841061]^

Plans with JT technique must be verified before treatment. In this study, we found that there was no significant difference in the γ passing rate between JT and NJT at the criteria of 3mm/3%, th10%, which is consistent with the result of Feng *et al*.^[@bibr17-1533033819841061]^ At the criteria of 2mm/2%, th10%, the pass rates of plans with JT are higher than NJT plans, with the *P* value \<.05. The γ passing rate can be affected by many factors, such as MLC dose leaf gap (DLG), MLC leakage and transmission factor, output factor, jaw moving speed, and position accuracy. In the Varian TPS model, DLG and MLC leakage and transmission factor can be tweaked a little from the measurement value. The DLG is a parameter that accounts for Varian's rounded MLC leaf ends and can affect the plan verification results a lot. The DLG value needs to be optimized at the stage of machine commissioning. The MLC leakage and transmission factor is an average value measured with large-volume ion chamber,^[@bibr18-1533033819841061]--[@bibr19-1533033819841061]^ such as PTW30013 with a sensitive volume of 0.6 cm^3^. However, it actually varies with different positions of the MLC.^[@bibr20-1533033819841061]^ The difference cannot be discovered with the criteria of 3mm/3%, th10% due to its small influence, but with the criteria of 2mm/2%, th10%, the difference shows up. The JT technique can minimize the jaw size and reduce the MLC leakage and transmission so that the pass rates will increase.

Field size is smaller in JT than in NJT, and the output factor is much more difficult to measure in small field. Swinnen *et al* reported that it was more accurate with the fixed field 3 × 3 cm^2^ than JT in the very small tumor treatment.^[@bibr21-1533033819841061]^ Our study showed good γ passing rates in brain metastasis with small fields. It could be that the volumes of our brain metastasis in this study are not so small. Because there is no output factor of field size \<3 × 3 cm^2^ in our PD model, PD can only measure the field size ≥3 × 3 cm^2^, so the verification results are still good in our brain metastasis plans. However, the smaller the tumor volume, the lesser the advantage of JT in dose reduction of OARs. So, when treating very small volume tumor with the field size less than 3 × 3 cm^2^, JT may not be a good choice.

In addition, we found that the MUs of JT plans were slightly higher than NJT, which was different from the article of Wu.^[@bibr7-1533033819841061]^ Target dose can also decrease with the decrease in the MLC transmission in JT; in order to compare the dose differences in OARs with the same tumor coverage, we renormalized the target dose. Meanwhile, the output factor is smaller in JT than in NJT due to the smaller jaw size, so the MU in JT should also be higher than NJT in order to get the same tumor dose. However, the increase in MU is very slight when using JT. The increase percentage of MU in NPC and single brain metastasis is 2.41% and 1.10%, respectively, which has little effect in the efficiency of treatment. Although the total MU is more in JT plan, the jaw size is smaller, most part of OARs is outside the field, and the jaw transmission is \<0.5%, so increase in MU has little impact on OAR doses.

Conclusion {#section8-1533033819841061}
==========

Jaw tracking technique can reduce the doses of OARs in static IMRT plans both in large and in small tumors, and the effect is more obvious in large tumors. The pass rates of plans with JT technique are also higher than NJT technique both in small (field size ≥3 × 3 cm^2^) and in large tumors. Although the MU of JT plan slightly increases, the effect in the efficiency of treatment is little, so it is recommended to use JT in static IMRT plan with the field size ≥3 × 3 cm^2^.
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